Table 3.
Frequency of Anti-Retroviral Intervention and Clinical Finding of HEIs and Their Mothers at Public Health Facilities in Dessie Town, Ethiopia, 2017 (N= 313)
| Variable | Categories | Frequency | Percentage |
|---|---|---|---|
| Maternal ARV intervention | Yes | 290 | 92.7 |
| No | 23 | 7.3 | |
| When were ARV drugs initiated | Prior to pregnancy | 187 | 64.5 |
| During pregnancy | 76 | 26.2 | |
| During labor/delivery | 16 | 5.5 | |
| After delivery | 11 | 3.8 | |
| ART drug during PMTCT intervention | TDF+3TC+EFV | 176 | 60.7 |
| AZT+3TC+EFV | 16 | 5.5 | |
| TDF+3TC+NVP | 27 | 9.3 | |
| AZT+3TC+NVP | 63 | 21.7 | |
| ABC+3TC+EFV | 8 | 2.8 | |
| Did the infant receive ARV prophylaxis? | Yes | 294 | 93.3 |
| No | 21 | 6.7 | |
| Abnormal findings in the infant suggesting HIV | Yes | 9 | 2.9 |
| No | 304 | 97.1 | |
| WHO clinical stage near/at delivery | Stage 1 and 2 | 299 | 95.5 |
| Stage 3 and 4 | 9 | 2.9 | |
| Not applicable | 5 | 1.6 |